SYNGENE2023-04-012023-06-30 SYNGENE2023-04-012023-06-30in-bse-fin:OneOperatingExpenses01Member SYNGENE2023-04-012023-06-30in-bse-fin:OneOperatingExpenses02Member SYNGENE2023-06-30 SYNGENE2023-04-012023-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member SYNGENE2023-04-012023-06-30in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 539268 SYNGENE NOTLISTED Syngene International Limited Equity 2023-04-01 2024-03-31 2023-07-26 2023-07-13 INR Millions First quarter 10:00:00 15:15:00 2023-07-26 2023-07-26 Not applicable Single segment tContract Research and Manufacturing Services 2023-04-01 2023-06-30 Unaudited Consolidated 8081000000.00 236000000.00 8317000000.00 2194000000.00 0.00 34000000.00 2154000000.00 105000000.00 1021000000.00 1580000000.00 7088000000.00 1229000000.00 0.00 1229000000.00 263000000.00 32000000.00 295000000.00 0.00 934000000.00 0.00 0.00 0.00 0.00 934000000.00 1091000000.00 2025000000.00 0.00 0.00 4020000000.00 10 2.33 2.32 0.00 0.00 2.33 2.32 1. The statement of unaudited standalone and consolidated financial results ( the Statements ) of Syngene International Limited ('the Company') for the quarter ended 30 June 2023 have been reviewed by the Audit Committee at their meeting held on 25 July 2023 and approved by the Board of Directors of the Company at their meeting held on 26 July 2023. The above Statements have been subjected to the limited review by the statutory auditor of the Company. The reports of the statutory auditor are unqualified. The Statements have been prepared in accordance with Indian Accounting Standards (‘Ind AS’) prescribed under Section 133 of the Companies Act, 2013 and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. 2. The consolidated financial results include the financial results of the Company - Syngene International Limited and the financial results of the following subsidiaries: i. Syngene USA Inc. ii. Syngene Scientific Solutions Limited iii. Syngene Manufacturing Solutions Limited The Company and the Subsidiaries are collectively referred to as 'the Group'. In addition to the above, the standalone and consolidated financial results also include the financial results in respect of Syngene Employees Welfare Trust. 3. The standalone and consolidated figures for quarter ended 31 March 2023 are the balancing figures between audited figures in respect of the full previous financial year and the published unaudited year to date figures upto the third quarter of the previous financial year which were subjected to limited review. 4. The Group operates in a single segment of providing Contract Research and Manufacturing Services. 5. On 26 April 2023, the Board of Directors of the Company have approved an allotment of 580,500 equity shares of Rs. 10/- (Rupees Ten each) of the Company to Syngene Employee Welfare Trust at face value pursuant to the shareholders’ approval at the Annual General Meeting on 24 July 2019 to allot fresh equity shares upto 1.67% of the paid-up equity capital of the Company in tranches for the purpose of implementation of the Syngene International Limited - Restricted Stock Unit Long Term Incentive Plan FY 2020. 6. On 26 April 2023, the Board of Directors recommended a final dividend of Rs. 1.25 per equity share of Rs. 10/- (comprising a regular dividend of Rs.0.5 per share and a special additional dividend of Rs. 0.75 per share to mark the 30th anniversary of the founding of the Company in November 1993). The proposed dividend is subject to the approval of the shareholders in the Annual General Meeting. 7. Events after reporting period: On 04 July 2023, the Company's Board of Directors have entered into a binding term sheet for acquiring Unit 3 biologics manufacturing facility in Bangalore, India, from Stelis Biopharma Limited (SBL). The Company will acquire Unit 3 on a slump sale basis for a gross value of Rs. 7,020 million. Subject to closing adjustments, the consideration for the transaction will be settled in cash. The transaction is expected to close within 90 days, subject to customary conditions, including receiving the required lender and regulatory approvals. Upon completion of the transaction, the site will add 20,000 litres of installed biologics drug substance manufacturing capacity for Syngene. The site has the potential for future expansion of up to a further 20,000 litres of biologics drug substance manufacturing capacity. It also includes a commercial scale, high speed, fill-finish unit – an essential capability for drug product manufacturing. 8. Effective 01 April 2023, the Company has transferred its operations in Hyderabad under slump sale arrangement to Syngene Scientific Solutions Limited ( SSSL ), a Wholly owned subsidiary of the Company. Foreign exchange fluctuation loss, net 155000000.00 Other expenses 1425000000.00 Items that will not be reclassified to profit or loss 15000000.00 15000000.00 3000000.00 Items that will be reclassified to profit or loss 1367000000.00 1367000000.00 288000000.00